Novo Nordisk doubles obesity sales in 2022

Wegovy and Saxenda set new records in fiscal 2022, during which particularly the former gave a strong performance near the end, exceeding analysts Q4 expectations by millions of dollars.
Photo: Novo Nordisk / Pr
Photo: Novo Nordisk / Pr
by mikkel aabenhus hemmingsen, translated by daniel pedersen

Although supply issues have plagued Novo Nordisk’s Obesity Care in large portions of 2022, the Danish drugmaker has still managed to break records at the end of fiscal 2022 for the rapidly growing business unit, revealed the annual report on Wednesday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading